Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs - Wikidata - wikimedia - TriplyDB

Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs

Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs

http://www.wikidata.org/entity/Q37308940

about

LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status Parkinson's disease proteins: Novel mitochondrial targets for cardioprotection The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice LRRK2 at the interface of autophagosomes, endosomes and lysosomes LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives Parkinson's disease: animal models and dopaminergic cell vulnerability Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases Two-Pore Channels and Parkinson's Disease: Where's the Link?Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.Targeting GTPases in Parkinson's disease: comparison to the historic path of kinase drug discovery and perspectives Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury.Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.LRRK2 and ubiquitination: implications for kinase inhibitor therapy The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research.Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling Genetic, structural, and molecular insights into the function of ras of complex proteins domains.Cellular processes associated with LRRK2 function and dysfunction LRRK2 Pathways Leading to Neurodegeneration.LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?LRRK2 and Autophagy.Models of LRRK2-Associated Parkinson's Disease.Targeting LRRK2 in Parkinson's disease: an update on recent developments.Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins.LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model.Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells.LRRK2 dephosphorylation increases its ubiquitination.Altered Expression of EPO Might Underlie Hepatic Hemangiomas in LRRK2 Knockout Mice.Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease?Effect of selective LRRK2 kinase inhibition on nonhuman primate lung.A homologue of the Parkinson's disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover.Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis.Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.Synthesis and In Vitro and In Vivo Evaluation of [3H]LRRK2-IN-1 as a Novel Radioligand for LRRK2.New developments in genetic rat models of Parkinson's disease.LRRK2 knockdown in zebrafish causes developmental defects, neuronal loss, and synuclein aggregation.

P2860

Q24300605-00F485B0-3705-4811-88B1-210DCA50EEE1 Q26781796-B9CBBD54-B393-4C3C-9261-2E810BAE7DDC Q26853537-006C58E4-4248-4A7F-A4E3-0608D4FEDA3A Q27007413-A3622277-F889-4005-BB2F-8B5CE46963D5 Q27308060-9577D1ED-5F22-4193-A567-7CC218236928 Q28078248-E6CAA309-9DA5-42C1-BE0F-CE4981C49FBE Q28078899-E071DC94-2F14-448E-AE99-C297057190EC Q28080503-22118A2E-F5C6-4325-B5E1-DAA1DAB1DE93 Q28116245-176F3528-6364-4C0E-BE28-5E949846322F Q28119192-5CB6E04F-5338-404C-9A56-C58D9A56C06B Q33703425-1DD7E7A7-D677-483B-B371-2967D44DD23F Q34552787-FCA7CB76-BB88-473F-9BBF-E132ECD85C19 Q35187475-C75E9DF6-8123-4DEF-8B79-A6217A508F8E Q35766417-BC2E733B-6E4E-4C9C-AD1B-A25CD9CCBC84 Q35925767-19B2E42B-5679-4373-952B-13E29F2286AA Q36185165-F598DCC3-4E1E-4C0E-88C9-D9CC62641BD1 Q37513500-07F3C244-594B-4814-8686-BAD26D547C06 Q37595673-79DE98CE-6DF9-4BB9-828D-2BCFED70FB05 Q38225040-3BBA1F7F-6884-4230-B765-8C83EA721D99 Q38433725-9E7AF2AD-AD09-4FC7-B430-B21AA997BABD Q38501861-1B9372A0-746B-4F52-AEBD-44300E115275 Q38620229-AE1D7770-1B65-42C9-86F4-5AA2018E70B9 Q38869514-0A2210F4-8242-44EC-B3FF-47EF1407DD78 Q39206443-0A7DED8B-68B9-4FE8-97FC-7CE0A53E4A79 Q39263032-3E68C4E4-F661-4A5F-A53D-580B8296C4EF Q41163700-FEFD1A18-EE14-48E2-8802-0ACCB1F628E6 Q41374126-5C2B4057-F45D-45FD-AFA6-4654FAB8364B Q41539639-79613717-F15D-46EB-BB6F-8FD3D4800541 Q41579661-40634BCA-2D43-40E0-BC10-FB1F12458E76 Q41785779-2465E946-FBAB-46B2-AF41-EFFFC97FC731 Q42369410-31B26FF4-B65E-451A-95FF-2CE7FD425639 Q45865514-C61523F3-E281-4F6E-8EBD-6F4BA56AFFE8 Q46777308-22CC2F73-13A3-479C-9D97-FE8625835C8F Q47127108-8D455608-F644-4F8B-91E9-38EE7B687172 Q47142767-D9B0C6B0-99D9-4643-9B23-2DE646277740 Q47288069-A6B0CFFF-BB76-41D4-BC3A-E581D267AE4F Q48003270-CE477558-1388-4235-B3A1-4E03E4CDD749 Q48132251-0D270AD4-C5A3-4BC7-AAF6-F1A2E230FBFC Q48502440-B54FABFC-EDE2-4679-8221-0948EEF1F31E Q48693369-83D3E2EE-B6FE-4B20-8CFA-90EF040896AB

P2860

Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs

http://www.wikidata.org/entity/Q37308940

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Loss of leucine-rich repeat ki ...... henotypes in peripheral organs

@en

Loss of leucine-rich repeat kinase 2

@nl

type

label

Loss of leucine-rich repeat ki ...... henotypes in peripheral organs

@en

Loss of leucine-rich repeat kinase 2

@nl

prefLabel

Loss of leucine-rich repeat ki ...... henotypes in peripheral organs

@en

Loss of leucine-rich repeat kinase 2

@nl

P1433

Q37308940-8BDE7902-9DF0-4900-8332-D54F8A95FD3D

P1476

Q37308940-B659CDCF-24E7-48FF-9EF8-364D91586119

P2093

Q37308940-0A4FFF77-B8FC-48EF-9F02-395A53B1B020

Q37308940-25589836-F24F-4232-BFD2-D2609DE6BB2F

Q37308940-2C79928D-F0B7-4718-AB1C-1885999FB2D6

Q37308940-50D6D8C8-F661-4ACF-BEAB-5BE3A0F91994

Q37308940-5D983204-DD8E-474A-8982-65CD604FD048

Q37308940-5F884E9B-8876-4C13-BD8D-B383262E1351

Q37308940-81B4731B-B19E-4239-99DA-592E59C9291A

Q37308940-8C289A8F-FF58-4666-A595-6A8456344B5D

Q37308940-918B81B6-FD52-4C45-B371-7C953CAA05B7

Q37308940-D5F6AA3B-698B-4BCC-B646-9702892562E6

P2860

Q37308940-012B7599-0D1E-40E4-82A7-59330598555E

Q37308940-0325748B-038A-4217-BB35-596D4D0208E3

Q37308940-129D05CA-4823-4972-A74D-20AD01FABABB

Q37308940-132A959B-7A87-41FE-B2F4-EC0A8F5F4C49

Q37308940-2001C7BE-C4B4-493E-B7D4-4E340B0F8910

Q37308940-2C385A80-E6BA-4996-B5B2-FDA4944AA194

Q37308940-2E5D8C19-B737-4A5E-860C-2C86CCCE9ADA

Q37308940-308F75B0-8D36-458E-898E-D259612F4CC8

Q37308940-35BC1578-488E-4CA9-B4E4-A1545E908F52

Q37308940-3B7C57B7-13E8-4B64-A3E3-D295A884ACE3

P304

Q37308940-AB1554BF-D29E-4AC4-96EA-CB579AC982A6

P31

Q37308940-9B23FF15-6D98-49FD-821E-2CEEF34EE5C1

P356

Q37308940-5E8202E8-F238-4FBA-8C3E-4E86035B220C

P407

Q37308940-90F563EB-C512-4E6C-A191-2487E19D44F5

P433

Q37308940-AB0033BC-DDD3-4C5E-B36F-FA0F77AD89C7

P478

Q37308940-1D3D16E9-7E90-4ABC-9D70-CB2E29A90CA6

P50

Q37308940-2938F151-309F-435F-AF50-4E7371E5E43C

P577

Q37308940-03533053-8EF7-4F04-9425-BA37F31881D9

P5875

Q37308940-E869BD2A-05FC-4D98-97F1-CAA59774058E

P698

Q37308940-919718AD-E027-4CC9-A8F4-97F4CD724AD1

P932

Q37308940-8FFDA13E-FDCE-4CD9-99B2-DBB5E3C394EF

P356

JOURNAL.PONE.0080705

P1433

P1476

Loss of leucine-rich repeat ki ...... henotypes in peripheral organs

@en

P2093

Brian K Fiske

http://www.w3.org/2001/XMLSchema#string

Charles K Meshul

http://www.w3.org/2001/XMLSchema#string

Cindy Moore

http://www.w3.org/2001/XMLSchema#string

George A Parker

http://www.w3.org/2001/XMLSchema#string

Julie S Varsho

http://www.w3.org/2001/XMLSchema#string

Kuldip D Dave

http://www.w3.org/2001/XMLSchema#string

Marco A S Baptista

http://www.w3.org/2001/XMLSchema#string

Mark A Frasier

http://www.w3.org/2001/XMLSchema#string

Melanie Greeley

http://www.w3.org/2001/XMLSchema#string

Melissa J Beck

http://www.w3.org/2001/XMLSchema#string

P2860

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity

Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?

Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology

Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice

Differences in immunolocalization of Kim-1, RPA-1, and RPA-2 in kidneys of gentamicin-, cisplatin-, and valproic acid-treated rats: potential role of iNOS and nitrotyrosine

Parkinson's disease

LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors.

Effects of subthalamic nucleus lesions and stimulation upon corticostriatal afferents in the 6-hydroxydopamine-lesioned rat

P304

e80705

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0080705

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Madeline J Churchill

P577

2013-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258639750

http://www.w3.org/2001/XMLSchema#string

P698

24244710

http://www.w3.org/2001/XMLSchema#string

P932

3828242

http://www.w3.org/2001/XMLSchema#string